AI in Regulatory Affairs Is Not a Feature — It’s an Infrastructure Decision

AI in Regulatory Affairs Is Not a Feature — It’s an Infrastructure Decision

Every day, I talk to regulatory leaders across the pharmaceutical industry, and almost without exception, the conversation eventually turns to AI. The question I hear most often is, “How can we use AI in regulatory affairs?” It’s a natural question, but frankly, it’s often the wrong one.

Most companies are still evaluating AI as a feature, a bolt-on capability: “Can AI write my cover letter?” or “Can AI classify my documents?” While these are valid use cases, approaching AI this way in a regulated environment is fundamentally flawed. The right question isn’t about specific features; it’s about this: “What infrastructure do I need so that AI can operate safely, compliantly, and effectively across my entire regulatory workflow?”

AI, especially large language models (LLMs), is not just another tool you add to your existing stack. It’s a foundational layer that demands robust governance, comprehensive audit trails, and stringent compliance controls from day one. Without this **AI regulatory affairs pharmaceutical compliance infrastructure**, you’re not just taking risks; you’re building a house of cards.

Why “Feature-Level” AI Fails in Pharma

Let me give you a few practical examples of why treating AI as a mere feature doesn’t cut it in our world:

• Data Leakage and Security: You bolt a public LLM like ChatGPT onto your document editor for quick summaries. Suddenly, confidential drug application data, proprietary research, or patient PII is flowing to a third-party server – OpenAI’s, for instance – with no audit trail, no control over its use, and no guarantee of privacy. This isn’t just a risk; it’s a compliance nightmare waiting to happen.
• Contextual Blind Spots: You add an AI classification feature to your RIM system. Great. But what if that AI can’t access related documents in your eTMF, or the broader context of your clinical trial data? It classifies with incomplete information, leading to errors, rework, and potentially non-compliant submissions. Each siloed AI feature perpetuates the very data fragmentation it’s supposed to help solve.
• Audit Trail Deficiencies: You build a one-off AI prototype for submission summarization. It works wonderfully during development. Then an inspector asks, “Show me the audit trail for every AI-assisted decision in this submission – how was the model trained, what data was used, what was the human review process, and where is the record of the AI’s output being accepted or rejected?” If your AI is a feature, chances are you’ll have nothing but a black box.

Each of these feature-level AI implementations creates its own silo, its own unique risk profile, and its own compliance gap. They’re often quick wins that lead to long-term headaches, especially when you’re dealing with the stringent requirements of 21 CFR Part 11 and other global regulatory standards.

AI, especially large language models, is not just another tool you add to your existing stack. It’s a foundational layer that demands robust governance, comprehensive audit trails, and stringent compliance controls from day one.

What Comprehensive AI Infrastructure for Regulatory Affairs Looks Like

When our team at DnXT started building out our AI capabilities, we didn’t ask, “What features can we add?” We asked, “What robust **AI regulatory affairs pharmaceutical compliance infrastructure** do we need to ensure safety, auditability, and scalability?” This led us to design a multi-layered approach:

1. The AI Gateway: This is our single, audited entry point for all AI interactions across the DnXT platform. Every request sent to an LLM, every response received, every prompt, and every output is logged and recorded. This isn’t just for security; it’s fundamental for auditability. Our gateway also handles multi-provider routing – meaning we can intelligently send a task to the best-suited model, whether it’s from Anthropic, OpenAI, or Azure OpenAI, because no single model is optimal for every regulatory task. Crucially, it includes PII detection and redaction *before* sensitive data leaves our secure environment for an external model.
2. Tenant Isolation: For a SaaS platform like ours, this is non-negotiable. Customer A’s AI interactions, data, and fine-tuning are completely walled off from Customer B’s. This isn’t just an API key separation; it’s about ensuring model context and learned patterns are isolated, maintaining data integrity and confidentiality at the highest level.
3. Role-Based AI Access: Not every user gets every AI capability. A regulatory associate might be authorized for document classification or initial metadata extraction. A senior director might have access to submission summarization. An administrator might initially have no AI access until they’re trained and authorized. This granular control is essential for managing risk and ensuring appropriate use.
4. Compliance-First Design: We embed 21 CFR Part 11 audit trails into every AI interaction. This means logging who initiated an AI action, what the input was, what the AI’s output was, and who reviewed/accepted/rejected it. We also focus on explainability for classification decisions – understanding *why* the AI made a certain categorization. And, critically, we build in human-in-the-loop gates for all high-stakes decisions. AI assists; humans decide.
5. Domain Grounding (RAG): This is perhaps the most vital component for accuracy in regulatory affairs. We use Retrieval Augmented Generation (RAG) to ground AI responses in the customer’s actual document corpus, submission history, and regulatory guidelines. This ensures that the AI’s suggestions and summaries are based on your specific, validated data, drastically reducing hallucinations and providing reliable, context-aware information. No more generic, potentially inaccurate regulatory advice from a general-purpose model.

Where DnXT Stands Today

We’re not just talking about this infrastructure; we’ve built it, and it’s processing real customer workloads. Our AI Gateway service is live, routing millions of tokens securely and compliantly. We support multiple LLM providers because we understand the nuanced demands of different regulatory tasks. We’ve integrated AI into core workflows – everything from intelligent document classification and metadata extraction to submission quality checks and content summarization.

But I want to be honest: AI in regulatory affairs isn’t a magic bullet. It can’t replace regulatory judgment. It can’t guarantee factual accuracy without robust RAG and human oversight. And it should never, ever make a final submission decision without thorough human review and approval. Our approach is about augmenting human expertise, not replacing it.

The Coming Inflection Point

The **AI regulatory affairs pharmaceutical compliance infrastructure** you build today will dictate your readiness tomorrow. I firmly believe that in 2-3 years, health authorities will not just tolerate AI; they will expect to see robust AI governance documentation as part of the submission process. They’ll want to understand your AI audit trails, your data security protocols, and your human-in-the-loop processes.

Companies that are building this infrastructure now will be ready. Companies that are still bolting on features will be scrambling, trying to retrofit compliance into an unsustainable architecture. This inflection point reminds me of the cloud migration a decade ago – the companies that built cloud-native won. The ones that merely “lifted and shifted” their legacy systems are still paying the cost.

Don’t ask how AI can be a feature. Ask how you can build the foundational **AI regulatory affairs pharmaceutical compliance infrastructure** to future-proof your regulatory operations. The answer to that question will define your competitive edge and your compliance posture for years to come.

Explore Our AI-Ready Platform